Sanofi India Limited
HEALTH/PHARMA
Sanofi
India launches Combiflam® Plus
-
A targeted, fast and effective OTC solution for headaches
Mumbai, February 15,
2013: Sanofi India
Limited (previously known as Aventis Pharma Limited) announced today the launch
of Combiflam® Plus, a targeted1, fast and effective solution
for headaches, which is also gentle on the stomach2. Combiflam® Plus
is a combination of paracetamol and caffeine. A line extension of one of Sanofi
India’s flagship brands Combiflam®, the launch of this new product marks the
company’s foray into the OTC headache segment in India.
While
announcing the launch, Anindya Chowdhury, Senior Director- Consumer
Healthcare, Sanofi India said, “Today’s hectic and stressful
lifestyles are impacting the quality of life and productivity of people. Data
suggests that over 70% of men and women experience an episode of headache every
month, and 36% suffer from it weekly3.
‘We are
pleased to introduce Combiflam® Plus (a
paracetamol and caffeine combination) to our consumers which is a targeted
solution for headaches. This combination is shown to have 89% incremental
analgesic effect (in terms of total pain relief) when compared with paracetamol
monotherapy4".
Caffeine has
been shown to have a synergistic and well documented adjuvant action when
combined with analgesics (painkillers). Research shows that adding caffeine to
an analgesic for e.g. paracetamol, increases the potency of the analgesic by
approximately 40%5.
|
Why Combiflam®
Plus?
|
|
Combiflam®
Plus (paracetamol and
caffeine combination) is a targeted1, fast and effective solution for
headaches, which is also gentle on the
stomach2.
|
|
A study assessing
total pain relief with the paracetamol and caffeine combination suggested an 89%
incremental analgesic effect when compared with Paracetamol
monotherapy4.
|
In a first of
its kind ‘Pack of 4s’ packaging in the headache category, Combiflam® Plus is
priced at Rs 9.50/-(MRP) and will be available in the states of
Uttar Pradesh, Maharashtra, Tamil Nadu, West Bengal, Punjab and Haryana
.
Combiflam®
Plus is a line
extension of Combiflam®, which has been a
trusted brand in the Indian pharmaceutical market for over 25 years, and is
present in ‘1 in every 3 households across
India’6.
About
Sanofi: Sanofi, a global and diversified
healthcare leader, discovers, develops and distributes therapeutic solutions
focused on patients’ needs. Sanofi has core strengths in the field of healthcare
with seven growth platforms: diabetes solutions, human vaccines, innovative
drugs, rare diseases, consumer healthcare, emerging markets and animal health.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE:
SNY).
In India,
Sanofi operates through five entities − Sanofi India Limited (previously known
as Aventis Pharma Limited), Sanofi-Synthelabo (India) Limited, Sanofi Pasteur
India Private Limited, Shantha Biotechnics Limited and Genzyme India Private
Limited.
References:
- Haag
G
et al. Self-medication of migraine and tension-type headache: summary of the
evidence-based recommendations of the Deutsche Migräne und
Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN),
the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische
Kopfwehgesellschaft (SKG). J
Headache Pain. 2011 Apr;12(2):201-17.
2.
http://www.tylenol.ca/adult-pain-relief/tylenol-ultra-relief-migraine-pain
(as assessed on February 08 2013)
3.
GFK Market Research
Findings 2012(5100 consumers, 16 centers)
4.
Migliardi JR,
Armellino JJ, Friedman M, Gillings DB, Beaver WT. Caffeine as an analgesic
adjuvant in tension headache. Clin Pharmacol Ther. 1994
Nov;56(5):576-86.
- Laska
EM et al. Caffeine as an analgesic adjuvant. JAMA. 1984 Apr 6;251(13):1711-8.
6.
Nielsen study on
Combiflam Pricing ( Oct'12)
Comments
Post a Comment